08:44 AM EST, 11/08/2024 (MT Newswires) -- Moderna ( MRNA ) said Friday that Health Canada has approved its mResvia vaccine to prevent lower respiratory tract disease caused by the respiratory syncytial virus in adults 60 years and older.

The company said mResvia is available in single-dose pre-filled syringes and is expected for delivery in Canada in early 2025.

Health Canada's approval, which is based on data from a phase 3 study conducted in about 37,000 adults aged 60 and older in 22 countries, followed approvals in the US, Europe and Qatar, Moderna ( MRNA ) said.

Price: 50.17, Change: -0.11, Percent Change: -0.22